Ellen M. van der Aar

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial

Toby M. Maher, Ellen M. van der Aar, Olivier Van de Steen et al. · The Lancet Respiratory Medicine · 2018 · 235 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +7

Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases

Luc Van Rompaey, René Galien, Ellen M. van der Aar et al. · The Journal of Immunology · 2013 · 234 citations · Full text

Life Sciences, Immunology, Pharmacology +12

Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634

Christel Menet, Stephen R. Fletcher, Guy Van Lommen et al. · Journal of Medicinal Chemistry · 2014 · 121 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Discovery and Optimization of an Azetidine Chemical Series As a Free Fatty Acid Receptor 2 (FFA2) Antagonist: From Hit to Clinic

Mathieu Pizzonero, Sonia Dupont, Marielle Babel et al. · Journal of Medicinal Chemistry · 2014 · 110 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Structure-activity relationships for chemical and glutathione S-transferase-catalysed glutathione conjugation reactions of a series of 2-substituted 1-chloro-4-nitrobenzenes

Ellen M. van der Aar, Tialda Bouwman, Jan N. M. Commandeur et al. · Biochemical Journal · 1996 · 21 citations · Full text

Life Sciences, Biochemistry, Chemistry +16